Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction
نویسندگان
چکیده
منابع مشابه
Role in Hypercholesterolemia Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction
Rainer H. Böger, Stefanie M. Bode-Böger, Andrzej Szuba, Philip S. Tsao, Jason R. Chan, : Its Role in Hypercholesterolemia Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 1998 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Da...
متن کاملAsymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
BACKGROUND Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. Because endothelial NO elaboration is impaired in hypercholesterolemia, we investigated whether plasma concentrations of ADMA are elevated in young, clinically asymptomatic hypercholesterolemic adults. We further studied whether such elevation of ADMA levels was correlated with im...
متن کاملAsymmetric Dimethylarginine (adma): a Mediator of Endothelial Dysfunction and a Novel Cardiovascular Risk Factor
Asymmetric dimethylarginine (ADMA) is involved in the pathogenesis of hypertension and atherosclerosis by inhibiting the generation of nitric oxide, an endogenous vasculoprotective molecule. Determination of ADMA helps to predict a patient`s probability of experiencing death or cardiovascular disease. A novel competitive ADMA-ELISA that has recently been developed and validated by us is a usefu...
متن کاملAsymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis
Atherosclerotic coronary heart disease is the leading cause of morbidity and mortality in industrialized countries, and endothelial dysfunction is considered a precursor phenomenon. The nitric oxide produced by the endothelium under the action of endothelial nitric oxide synthase has important antiatherogenic functions. Its reduced bioavailabilty is the beginning of the atherosclerotic process....
متن کاملAsymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
There is a growing clinical evidence to support the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase is a new independent cardiovascular risk factor. ADMA mediates endothelial dysfunction in lipid disorders, coronary artery disease, chronic heart failure, diabetes mellitus and hypertension. The aim of this review was to summarize the latest ev...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 1998
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.98.18.1842